Santen Ventures co-led a series B round to bring TAU faculty-founded Belkin Laser's funding total to $16.3m.

Belkin Laser, Israel-based glaucoma laser treatment developer linked to Tel Aviv University faculty, has closed a $12.3m series B round co-led by Santen Ventures, the corporate venturing fund for pharmaceuticals firm Santen.
The round was co-led by Rimonci Capital and also included eye care product developer BioLight Life Science, ophthalmological holding company C-Mer Eye Care and CR-CP Life Science Fund, a joint venture of conglomerates China Resources and Charoen Pokphand.
Founded in 2013, Belkin Laser is working on…